Trial Profile
Phase 3, double blinded, placebo controlled study of the effects of 12 weeks DPP-IV inhibitor treatment on secretion and action of the incretin hormones in patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Dipeptidyl peptidase 4 inhibitors
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 06 Nov 2012 Investigational drug identified as Sitagliptin as reported by European Clinical Trials Database.
- 05 Jan 2007 New trial record.